MiniVax’s Pneumocystis Vaccine Candidate Induces Significant anti-Pneumocystis Antibody Responses and Reduced Fungal Load
6/4/2012 2:53:10 PM
NEW ORLEANS--(BUSINESS WIRE)--MiniVax, Inc. (MiniVax), a company focused on the development of novel treatments for opportunistic bacterial and fungal infections, recently announced an update on the progress of its Pneumocystis (PC) vaccine candidate at the 2012 America Thoracic Society (ATS) Conference in San Francisco, CA. The presented poster, entitled “Novel Vaccine Strategies to Prevent Infection with Murina,” indicates that DNA immunization with MiniVax’s proprietary mini-Kexin technology results in significant anti-Pneumocystis antibody responses as well as a reduced fungal load. These data support further development of MiniVax’s technology as a vaccine for Pneumocystis pneumonia (PCP). MiniVax is taking this lead program, a vaccine for PCP, into full product development and is now undertaking studies prior to clinical development.
comments powered by